Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $174

Benzinga · 1d ago
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $110 to $174.